Trials
Search / Trial NCT05641935

Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

Launched by JOHN EISENBREY · Nov 29, 2022

Apply for Trial

Trial Information

Current as of February 05, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is exploring how effective a special type of ultrasound, called contrast-enhanced ultrasound (CEUS), is in detecting recurrent renal cell carcinoma (RCC) after patients have undergone treatment like cryotherapy or microwave therapy. The goal is to see if CEUS can help doctors find and track the return of kidney cancer more effectively after these treatments.

To participate in this trial, you need to be at least 18 years old and have previously received cryotherapy or microwave therapy for RCC. You should also have had a CE-MRI or CE-CT scan before your treatment and be scheduled for another one within four weeks of the CEUS study. It's important that you're medically stable, and if you are a woman of child-bearing age, you will need a negative pregnancy test. Participants will receive CEUS imaging to help monitor their condition, and they will be part of a study that aims to improve how doctors diagnose and manage recurrent kidney cancer. If you have any serious health issues, or if you are allergic to the contrast agent used in the ultrasound, you may not be eligible for this study.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Previously received cryotherapy or microwave therapy of RCC
  • • Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
  • • Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
  • • Be at least 18 years of age
  • • Be medically stable
  • • If a female of child-bearing age, must have a negative pregnancy test
  • • Have signed Informed Consent to participate in the study
  • Exclusion Criteria:
  • • Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
  • • Patients with known sensitivities to the components of Lumason

About John Eisenbrey

John Eisenbrey is a dedicated clinical trial sponsor focused on advancing medical research and innovative therapies. With a commitment to improving patient outcomes, Eisenbrey oversees a range of clinical trials that aim to evaluate the safety and efficacy of new treatments across various therapeutic areas. Leveraging extensive expertise in clinical development, regulatory compliance, and patient engagement, the organization fosters collaboration among researchers, healthcare professionals, and stakeholders to facilitate the successful progression of trials. Through a patient-centered approach and a robust ethical framework, John Eisenbrey strives to contribute to the advancement of healthcare and the well-being of communities.

Locations

Philadelphia, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials